TriSalus Life Sciences Inc

Company Profile

• Business description

  TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

• Contact

  6272 W. 91st Avenue
  WestminsterCO80031
  USA

  T: +1 888 321-5212

  https://www.trisaluslifesci.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Medical Devices

  Fiscal Year End

  31 December 2026

  Employees

  102